Journal of Medicinal Chemistry · 2014 · 45 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsFragment-based Drug DesignFragment-based Lead DiscoveryFragment-based OptimizationHit-to-lead OptimizationLead Compound DesignLead DiscoveryDna Synthesis InhibitionEnzymatic Dna SynthesisFragment Screening LibrariesFragment-based Library ConstructionKinase Inhibitor Library DesignStructure-based Lead DiscoveryStructure-based Lead IdentificationStructure-guided Lead Discovery
M. tuberculosis thymidylate kinase is an essential enzyme for DNA synthesis. The study aimed to discover novel inhibitors of Mtb TMK by conducting a high‑throughput biochemical screen and an NMR‑based fragment screen, identifying two new inhibitor classes. The authors performed a hit‑to‑lead campaign that included co‑crystal structures of cyanopyridone subseries with Mtb TMK and used fragment‑based lead generation, crystal structures, and SAR to enhance potency.
M. tuberculosis thymidylate kinase (Mtb TMK) has been shown in vitro to be an essential enzyme in DNA synthesis. In order to identify novel leads for Mtb TMK, we performed a high throughput biochemical screen and an NMR based fragment screen through which we discovered two novel classes of inhibitors, 3-cyanopyridones and 1,6-naphthyridin-2-ones, respectively. We describe three cyanopyridone subseries that arose during our hit to lead campaign, along with cocrystal structures of representatives with Mtb TMK. Structure aided optimization of the cyanopyridones led to single digit nanomolar inhibitors of Mtb TMK. Fragment based lead generation, augmented by crystal structures and the SAR from the cyanopyridones, enabled us to drive the potency of our 1,6-naphthyridin-2-one fragment hit from 500 μM to 200 nM while simultaneously improving the ligand efficiency. Cyanopyridone derivatives containing sulfoxides and sulfones showed cellular activity against M. tuberculosis. To the best of our knowledge, these compounds are the first reports of non-thymidine-like inhibitors of Mtb TMK.
23